Adding metastasis-directed radiation therapy boosts progression-free survival in metastatic pancreatic cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients with oligometastatic pancreatic cancer. Findings from the multicenter EXTEND trial were first presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. At a median follow-up of 17.3 months, PFS was 10.3 months in patients who received metastasis-directed therapy (MDT) plus chemotherapy compared to only 2.5 months in those who received standard...